Clinical Trial

A Research Study to Investigate the Efficacy and Safety of HRS9531 Tablets in Participants With Type 2 Diabetes Mellitus

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The aim of the trial is to investigate the efficacy and safety of HRS9531 tablets versus placebo in participants with type 2 diabetes mellitus who failed to achieve adequate glycemic control on lifestyle intervention alone or on a stable dose of metformin. This study will last 20 weeks.
Protocol Amendment History 1 change
critical Recruitment opened 2026-07-24
Trial Details
NCT Number NCT07599410
Lead Sponsor Fujian Shengdi Pharmaceutical Co., Ltd.
Conditions T2DM
Enrollment 240 participants
Start Date 2026-07-14
Primary Completion 2027-05 (estimated)
Study Completion 2027-07 (estimated)
Updated on ClinicalTrials.gov 2026-07-23